Next Article in Journal / Special Issue
Docking into Mycobacterium tuberculosis Thioredoxin Reductase Protein Yields Pyrazolone Lead Molecules for Methicillin-Resistant Staphylococcus aureus
Previous Article in Journal
Fused-Ring Oxazolopyrrolopyridopyrimidine Systems with Gram-Negative Activity
Previous Article in Special Issue
The Search for Herbal Antibiotics: An In-Silico Investigation of Antibacterial Phytochemicals
Article Menu

Export Article

Open AccessReview
Antibiotics 2017, 6(1), 3; doi:10.3390/antibiotics6010003

Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action

1
Insititute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Lisbon 1349-008, Portugal
2
Institute of Medical Microbiology and Immunobiology, University of Szeged, Szeged 6720, Hungary
3
Unidade de Microbiologia Médica, Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon 1349-008, Portugal
*
Author to whom correspondence should be addressed.
Academic Editor: William R. Schwan
Received: 8 October 2016 / Revised: 29 December 2016 / Accepted: 5 January 2017 / Published: 14 January 2017
(This article belongs to the Special Issue Discover New Antibiotics 2016)
View Full-Text   |   Download PDF [1054 KB, uploaded 14 January 2017]   |  

Abstract

This review presents the evidence that supports the use of thioridazine (TZ) for the therapy of a pulmonary tuberculosis infection regardless of its antibiotic resistance status. The evidence consists of in vitro and ex vivo assays that demonstrate the activity of TZ against all encountered Mycobacterium tuberculosis (Mtb) regardless of its antibiotic resistance phenotype, as well as in vivo as a therapy for mice infected with multi-drug resistant strains of Mtb, or for human subjects infected with extensively drug resistant (XDR) Mtb. The mechanisms of action by which TZ brings about successful therapeutic outcomes are presented in detail. View Full-Text
Keywords: antibiotic resistant pulmonary tuberculosis; thioridazine; in vitro activity; ex vivo activity; in vivo activity (murine model and human trails); the non-killing macrophage; enhancement of intracellular killing of Mtb by thioridazine; mechanism of actions of thioridazine antibiotic resistant pulmonary tuberculosis; thioridazine; in vitro activity; ex vivo activity; in vivo activity (murine model and human trails); the non-killing macrophage; enhancement of intracellular killing of Mtb by thioridazine; mechanism of actions of thioridazine
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Amaral, L.; Viveiros, M. Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action. Antibiotics 2017, 6, 3.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibiotics EISSN 2079-6382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top